BRF113928: A Phase II study of the selective BRAF kinase inhibitor
GSK2118436 in subjects with advanced non-small cell lung cancer and BRAF mutations
This is a clinical trial of GSK2118436 that will be administered by mouth which is investigational.
IRB Protocol #
ANNA WYNFIELD at (720)848-5278 or ANNA.WYNFIELD@UCDENVER.EDU
University of Colorado Hospital University of Colorado Hospital
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last up to 2 years. A follow up period will consist of phone contact and clinic visits. // Eligibility criteria include but are not limited to 18 years or older with non-small cell lung cancer.Eligibility criteria include but are not limited to 18 years or older with non-small cell lung cancer.